INTRODUCTION AND OBJECTIVES: CO 2 fractional laser (MonaLisa Touch) for treatment of vestibulodynia via a vestibular probe has been found clinically useful in a pilot study. A 3-site, prospective, double-blind, sham-controlled investigator-initiated research study was performed to further examine the safety and efficacy of CO 2 fractional laser delivery in women with vestibulodynia.
METHODS: Subjects meeting inclusion and exclusion criteria were randomized to active or sham treatment 2:1. Changes were assessed on multiple outcome measures, including cotton swab test at 1:00, 3:00, 5:00, 6:00, 7:00, 9:00 and 11:00 positions, Female Sexual Function Index (FSFI) pain domain and total score, Female Sexual Distress Score (FSDS-R), and O'Leary/Sant Voiding and Pain Indices (ICSI/ICPI). Each arm consisted of 3 treatments 4 weeks apart (weeks 0 e 8). Follow-up visits were completed at weeks 12 and 16. Subjects assigned to sham were crossed over to active treatment at 12 weeks, administered 3 active treatment sessions with additional follow-up.
RESULTS: This is an interim analysis of the first 53 subjects. Cotton swab test scores in subjects assigned to active treatment decreased at visits 3-6, whereas no laser therapy (sham arm) resulted in minimal changes. Change from baseline in cotton swab test scores was significantly reduced after active treatment at week 12 (mean [ 1.05; 95% CI [-1.21, -0.89 CONCLUSIONS: These data from an interim exploratory analysis suggest that CO 2 fractional laser therapy in women with vestibulodynia improves subjective measures of pain and pain related to sexual activity, and also decreases pain symptoms and bother related to bladder voiding.
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PD20-09 ONOBOTULIUMTOXIN A VERSUS KENALOG FOR INTRAVAGINAL TRIGGER POINT INJECTIONS IN THE TREATMENT OF CHRONIC PELVIC PAIN
Jamie Bartley*, Lansing, MI; Laura Nguyen, Hamilton, Canada; Deborah Hasenau, Jason Gilleran, Larry Sirls, Esther Han, Lauren Tenneyson, Kenneth Peters, Royal Oak, MI INTRODUCTION AND OBJECTIVES: Chronic pelvic pain in women is often due to pelvic muscle dysfunction and hypertonicity. In this study we compared outcomes of patients with chronic pelvic pain undergoing transvaginal trigger point injections (TPI) with triamcinolone (steroid) vs. onabotulinumtoxinA (Botox).
METHODS: A prospective double-blind study was conducted. Patients were randomized (1:1) to receive in-office pelvic floor muscle injections with either a mixture of triamcinolone and ropivacaine followed by saline or injections of ropivacaine followed by a mixture of Botox 200 units and saline. Three bilateral injections were performed on each side of the pelvic floor. Statistical analysis compared the treatment groups at baseline and 1-month, 3-month and 6-month post-injection. RESULTS: Twenty-one patients underwent TPI (11 steroid, 10 Botox). Primary diagnosis included myalgia, urinary system related symptoms, muscle spasms, and chronic pelvic pain. There was no statistical difference in baseline demographics or prior treatment. The median pre-injection pain score for the Steroid group was lower than the Botox group (5 (range: 4-7) vs 6 (range: 5-8), respectively; p[ 0.015). At 1 month, there was no difference in median Numerical Rating Scale (NRS) pain scores between groups; n[9) ; p [ 0.82. The change in median NRS scores between 1 month and baseline was no different between groups (Steroid: -1 (range -2 to þ3) vs. Botox: -2 (range -4 to 0); p [ 0.072. The numbers for 3 and 6 months were too small for comparison but are presented in Table 1 . There is no difference between groups at baseline or at one month follow up on Brief Pain Inventory (BPI) measures or GRA measures. 90% (Steroid) and 89% (Botox) at 1month and 100% at 3 and 6 months (both groups) would recommend the same TPI to a friend. Regardless of the initial treatment received, approximately 40% of the patients from each group elected to receive steroid TPI at 1-month follow-up.
CONCLUSIONS: There was no difference in NRS pain scores at 1 month in patients that received TPI with triamcinolone compared to Botox. Patients in both groups would recommend TPI equally to a friend.
